Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Bristol-Myers Squibb
(NY:
BMY
)
54.32
-1.45 (-2.60%)
Official Closing Price
Updated: 7:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Bristol-Myers Squibb
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Bristol Myers Squibb Receives U.S. Food and Drug Administration sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
August 21, 2024
From
Bristol Myers Squibb
Via
Business Wire
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
August 20, 2024
With yields above 4%, these stocks could do a lot to boost your passive income stream
Via
The Motley Fool
Check Out What Whales Are Doing With BMY
August 16, 2024
Via
Benzinga
Smart Money Is Betting Big In BMY Options
August 09, 2024
Via
Benzinga
Smart Money Is Betting Big In BMY Options
August 06, 2024
Via
Benzinga
European Medicines Agency Validates Bristol Myers Squibb’s Application for CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
August 19, 2024
From
Bristol Myers Squibb
Via
Business Wire
Where Will Bristol Myers Squibb Be in 5 Years?
August 18, 2024
The drugmaker will go through key changes by the end of the decade.
Via
The Motley Fool
3 High-Yield Dividend ETFs to Buy to Generate Passive Income
August 18, 2024
ETFs offer a good way to own a diversified portfolio of income-producing equities.
Via
The Motley Fool
Topics
ETFs
Biden Administration Targets $6B Savings Through Medicare Drug Price Negotiations
August 15, 2024
Medicare drug price negotiations, enabled by the Inflation Reduction Act, are set to save the U.S. government $6 billion.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol Myers' German Partner Evotec Plans Layoffs, Cites 'Challenging Revenues, Profitability'
August 14, 2024
Evotec reports a rise in Q2 sales to $201.12M but posts an EPS loss of $0.54. CEO Christian Wojczewski cites market challenges and outlines cost-cutting measures, including a 7% workforce reduction.
Via
Benzinga
Topics
Workforce
Exposures
Layoff
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
August 13, 2024
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and...
Via
Benzinga
The 3 Best Healthcare Stocks to Buy in August 2024
August 12, 2024
These are the best healthcare stocks that could bring in massive returns to the investors in the future. Do not miss out on this opportunity.
Via
InvestorPlace
Bristol-Myers Squibb Co: Is It A Buy?
August 11, 2024
As part of an ongoing series, we typically conduct an analysis on one of the companies in our screens each week. This week, we thought we’d take a look at one of the cheapest stocks in our screens:...
Via
Talk Markets
3 Stocks Retirees Should Absolutely Love
August 10, 2024
All of these stocks can provide steady income to retired investors.
Via
The Motley Fool
3 Biotech Stocks With Promising Drug Pipelines: August 2024
August 08, 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval.
Via
InvestorPlace
Exposures
Product Safety
Bristol Myers Squibb Terminates Cancer Drug Development Program With Agenus
August 05, 2024
Agenus reports that Bristol Myers Squibb (NYSE: BMY) is ending their 2021 agreement, returning the TIGIT bispecific antibody AGEN1777. This decision is part of Bristol Myers' broader pipeline strategy...
Via
Benzinga
Worried About a Market Correction? 2 High-Yield Dividend Stocks You Can Buy Now and Hold Forever.
August 05, 2024
Recent market pressure could worsen, but that won't stop these successful businesses from raising their dividend payouts.
Via
The Motley Fool
MarketBeat Week in Review – 7/29 - 8/2
August 03, 2024
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
The 3 Biggest Earnings Beats for Q2 as of August 1, 2024
August 01, 2024
The stocks serving up the biggest earnings beats may just go on to offer investors fabulous returns going forward.
Via
InvestorPlace
Topics
Earnings
Exposures
Financial
8 Health Care Stocks With Whale Alerts In Today's Session
August 01, 2024
Via
Benzinga
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
August 01, 2024
These cheap value stocks are priced right for any bargain hunters seeking deals in the market at the moment.
Via
InvestorPlace
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?
July 31, 2024
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates.
Via
InvestorPlace
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
July 31, 2024
Investors should consider the long term prospects of the following three healthcare stocks as the U.S. population ages.
Via
InvestorPlace
Post-it Manufacturer 3M Sticks Landing While Ford Tanks: Biggest Beats And Misses From Earnings Season So Far
July 30, 2024
3M soared over 20% since it reported strong earnings on July 26, while Ford is down over 20% since its report on July 24.
Via
Benzinga
Bristol Myers, Johnson & Johnson, AbbVie, AstraZeneca Expect Minimal Impact From Upcoming Medicare Price Negotiations
July 30, 2024
Top pharmaceutical companies including Bristol Myers, Johnson & Johnson, AbbVie, and AstraZeneca foresee limited impact from the 2026 Medicare drug price cuts, easing initial industry concerns.
Via
Benzinga
10 Health Care Stocks Whale Activity In Today's Session
July 30, 2024
Via
Benzinga
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
July 30, 2024
The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)...
Via
Benzinga
Exposures
COVID-19
Market Momentum: Your Weekly Financial Forecast
July 30, 2024
Originally published at VolumeLeaders What to expect for July 29- August 02, 2024
Via
Benzinga
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
July 30, 2024
A lowered outlook for 2024 and upcoming patent expirations have investors concerned about this pharmaceutical giant's dividend program.
Via
The Motley Fool
Topics
Intellectual Property
Exposures
Intellectual Property
< Previous
1
2
3
4
5
6
7
8
9
...
65
66
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.